Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis
Background: In patients with heart failure (HF), randomized controlled trials (RCTs) of sodium-glucose transporter-2 inhibitors (SGLT-2is) have proven to be effective in decreasing the primary composite outcome of cardiovascular death and hospitalizations for HF. A recently published meta-analysis s...
Main Authors: | Frederick Berro Rivera, Vincent Anthony S. Tang, Deogracias Villa De Luna, Edgar V. Lerma, Krishnaswami Vijayaraghavan, Amir Kazory, Nilay S. Shah, Annabelle Santos Volgman |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-02-01
|
Series: | American Heart Journal Plus |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602223000137 |
Similar Items
-
Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences
by: Jean François Ndiaye, et al.
Published: (2023-03-01) -
Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion
by: Aida Lydia, et al.
Published: (2022-12-01) -
SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
by: Yajiao Wang, et al.
Published: (2023-01-01) -
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
by: Jonathan C. H. Chan, et al.
Published: (2023-02-01) -
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
by: Mahmoud E. Youssef, et al.
Published: (2023-03-01)